These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27384190)

  • 1. Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells.
    Nakano T; Inoue R; Kimura T; Suzumura H; Tanino T; Yamazaki Y; Yoshikawa K; Tatemichi M
    Adv Ther; 2016 Aug; 33(8):1452-9. PubMed ID: 27384190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
    Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
    Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
    J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study.
    Kobayashi H
    J Ocul Pharmacol Ther; 2012 Jun; 28(3):245-50. PubMed ID: 22283238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH; Medeiros FA; Slight JR; Weinreb RN
    Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma.
    Nakamoto K; Yasuda N
    J Glaucoma; 2007; 16(4):352-7. PubMed ID: 17570997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost.
    Li Yim JF; Montgomery DM
    Curr Med Res Opin; 2011 Aug; 27(8):1499-502. PubMed ID: 21651425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
    March WF; Ochsner KI
    Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
    Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
    Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients.
    Wang TH; Huang JY; Hung PT; Shieh JW; Chen YF
    J Formos Med Assoc; 2004 May; 103(5):369-73. PubMed ID: 15216404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
    Hayashi K; Yoshida M; Sato T; Manabe SI
    Am J Ophthalmol; 2019 Sep; 205():91-98. PubMed ID: 30902694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.
    Greig SL; Deeks ED
    Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
    Tsukamoto H; Noma H; Matsuyama S; Ikeda H; Mishima HK
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):170-3. PubMed ID: 15857284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].
    Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.